NYSE:MRK News 23 January 2026 - 7 February 2026

Merck shares closed up 1.8% at $121.93 Friday after Health Canada approved its ENFLONSIA RSV antibody for infants. Guggenheim raised its price target to $140. Insider filings showed three executives sold shares this week. Merck’s stock ended just below its 52-week high, with about 13 million shares traded.

Merck shares rose about 2% to $120.72 Thursday after forecasting 2026 sales and profits below Wall Street estimates, citing patent expiries on older drugs. The company reported Q4 global sales of $16.4 billion and non-GAAP EPS of $2.04, and expects 2026 sales of $65.5–$67.0 billion. Health Canada approved ENFLONSIA for RSV prevention in infants. FDA review of WINREVAIR is set for September 21, 2026.

Merck shares rose 2.8% to $119.11 by midday Wednesday after the company beat Q4 expectations, but projected 2026 revenue of $65.5–$67.0 billion, below analyst forecasts. Keytruda sales climbed 7% while Gardasil dropped 34% on weak China demand. The company cited a $2.5 billion hit from generic drugs and U.S. pricing pressure. Investors remain focused on Merck’s ability to offset declines in older products.

Merck shares rose 2.2% in after-hours trading Tuesday, closing at $115.84 after the company’s 2026 revenue forecast missed Wall Street estimates. The drugmaker cited a $2.5 billion hit from patent expirations, Medicare price talks, and weaker COVID-19 pill sales. Investors are watching Keytruda demand, Gardasil’s China performance, and FDA decisions expected later in 2026.

Merck shares rose 3.1% to $116.86 after fourth-quarter earnings beat estimates, with Keytruda sales up 7% to $8.37 billion. The company forecast 2026 sales of $65.5–$67.0 billion, below Wall Street expectations, citing patent expirations and pricing pressure. Gardasil sales fell 34% to $1.03 billion. The FDA accepted Merck’s application for Winrevair, with a decision expected by September 2026.

Merck shares fell 0.6% to $107.57 after reports said talks to buy Revolution Medicines stalled over price. Revolution stock dropped 17%. The potential $28–32 billion deal would have given Merck access to Revolution’s late-stage cancer drug. Investors await Merck’s Feb. 3 earnings call for updates on future deals and 2026 guidance.